BOCA RATON, Fla., Jul. 17, 2017 /PRNewswire/ -- TransMedia
Group (www.TransMediaGroup.com) to roll on layers of publicity
to introduce Venodol, a new over-the-counter analgesic
product for the treatment of chronic pain with cobra venom
as its active ingredient.
TransMedia said it plans to showcase Venodol's
anti-inflammatory chronic pain relieving potential, while
presenting the roll-on product as a non-addictive
alternative to opioid and steroidal analgesics.
"We firmly believe Venodol is a gentler and safer
approach to chronic pain relief," said Dr. Paul Reid, consulting advisor to Caretta
Therapeutics, LLC, Venodol's manufacturer.
TransMedia Group says it will issue news releases, viral
hashtags and conduct a variety of PR activities that will create
national media exposure, some of it featuring credible
spokespersons for Venodol.
As part of the PR campaign, TransMedia Group intends to partner
with health publications in gathering feedback from product
reviewers and reporting on Venodol's effectiveness in relieving
chronic pain on a regular basis.
"We want to dispel any stigma around the use of cobra
venom in a product for the treatment of chronic pain, and highlight
its therapeutic potential to provide long-term relief," said
TransMedia PR Director Rebecca
Shpektor.
The makers of Venodol said their selection of TransMedia
Group for publicity was based on the firm's history in successfully
launching pain relief consumer products into drug store, mass
merchandise and warehouse chains.
Media contact: Alexandra Flugel 561-750-9800 x2300;
alex@transmediagroup.com.
Forward-Looking Statements
Statements in this press release that are not purely historical
are forward-looking statements. Forward-looking statements herein
include statements regarding Caretta Therapeutics' efforts to
develop and commercialize Venodol, and to achieve its stated
benchmarks including, without limitation, statements relating to if
and when Caretta Therapeutics will succeed in making available
products it is developing; and the benefits of Venodol. Actual
outcomes and actual results could differ materially from those in
such forward-looking statements. The forward-looking statements
contained herein are made only as of the date of this press release
and TransMedia Group undertakes no obligation to publicly update
such forward-looking statements to reflect subsequent events or
circumstances.
View original
content:http://www.prnewswire.com/news-releases/transmedia-group-retained-to-publicize-launch-of-venodol-a-new-over-the-counter-roll-on-chronic-pain-relief-product-300488757.html
SOURCE TransMedia Group